Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1.
The nuclear protein high-mobility group box chromosomal protein 1 (HMGB1) was recently described to act as a pro-inflammatory cytokine and as a late mediator of severe sepsis and septic shock. The protein is released from monocytes in response to endotoxin and activates monocytes and endothelial cells through nuclear factor kappa B. We have previously demonstrated that the B-box of HMGB1 mediates a pro-inflammatory effect on endothelial cells including the upregulation of cell-adhesion molecules and release of interleukin (IL)-8 and granulocyte colony-stimulating factor. Here, we report that HMGB1 is released from human umbilical vein endothelial cells (HUVEC) in response to lipopolysaccharide (LPS) and tumour necrosis factor (TNF)-alpha. A nuclear relocation of HMGB1 to the cytoplasm was seen at 4 h. Subsequently, high amounts of HMGB1 could be seen in the supernatants from stimulated cells after 16 h. It was also observed that the pro-inflammatory activity of HMGB1 is sensitive to dexamethasone. Interestingly, the HMGB1-induced TNF-alpha release from monocytes could be inhibited by either the A-box of the protein or the p38 inhibitor CNI-1493, but neither had any inhibitory effects on the HMGB1-dependent upregulation of cell-adhesion molecules on HUVEC. Altogether, these results suggest that HUVEC may be an important source of HMGB1 secretion in response to systemic infection and that endothelial cells and monocytes may use different signalling pathways.
Mullins
G E
GE
Department of Medicine, Centre for Infectious Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden.
Sunden-Cullberg
J
J
Johansson
A-S
AS
Rouhiainen
A
A
Erlandsson-Harris
H
H
Yang
H
H
Tracey
K J
KJ
Rauvala
H
H
Palmblad
J
J
Andersson
J
J
Treutiger
C J
CJ
D002448:Cell Adhesion / Q000187:drug effects; D003907:Dexamethasone / Q000494:pharmacology; D042783:Endothelial Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D005938:Glucocorticoids / Q000494:pharmacology; D024243:HMGB1 Protein / Q000378:metabolism*; D006801:Humans; D006835:Hydrazones / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000276:immunology; D009000:Monocytes / Q000187:drug effects; D009504:Neutrophils / Q000187:drug effects*; D021381:Protein Transport; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D014471:Umbilical Veins / Q000276:immunology / Q000378:metabolism*; D000813:Anilides; D006146:Guanidines
D003907:Dexamethasone; D005938:Glucocorticoids; D024243:HMGB1 Protein; D006835:Hydrazones; D007166:Immunosuppressive Agents; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; C097256:semapimod; D000813:Anilides; D006146:Guanidines